Loading clinical trials...

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE2

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

A Pilot Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

NCT00106405•Forest Laboratories

View on ClinicalTrials.gov

Summary

Bipolar disorder affects 2.4 million adults in the USA between the ages of 18-65 and has considerable economic impact on our society. Bipolar mania accounts for 1 in 7 psychiatric emergencies and is associated with significant morbidity and mortality. The purpose of the study is to evaluate the safety and efficacy of open-label memantine in the acute management of adults with bipolar I disorder hospitalized for mania.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must have a documented clinical diagnosis of bipolar I disorder and must be currently experiencing a manic or mixed episode.
•Patients must be voluntarily hospitalized with a primary diagnosis of mania.

Exclusion Criteria

•Rapid cycling bipolar disorder.
•Suicidal risk.
•First manic episode.
•ECT, clozapine or a depot neuroleptic in the past 3 months.
•Substance dependence.
•Known HIV infection.
•Co-morbid serious, uncontrolled systemic illness.

Locations (6)

Synergy Clinical Research Center

National City, California, United States

Sheppard Pratt Health System

Baltimore, Maryland, United States

St. Charles Psychiatric Associates

Saint Charles, Missouri, United States

Psychiatric Professional Services, Inc.

Cincinnati, Ohio, United States

Rebecca Sealy Hospital

Galveston, Texas, United States

University Hills Clinical Research

Irving, Texas, United States

Key Dates

Start Date

February 1, 2005

Primary Completion Date

November 1, 2005

Completion Date

November 1, 2005

Last Updated

March 5, 2012

Enrollment

ACTUAL participants

Conditions

Bipolar Disorder

Interventions

Memantine HCl

DRUG

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918

Treatment Resistant DepressionMajor Depressive Episode+5 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913

ManiaBipolar Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

Inclusion Criteria

Exclusion Criteria

University of Iowa Interventional Psychiatry Service Patient Registry

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations

CBT-CP for Veterans With SMI

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Early Intervention for Youth at High Risk for Bipolar Disorder